- Home
- ALGS vs GRF Comparison
ALGS vs GRF Comparison
Compare ALGS & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- GRF
- Stock Information
- Founded
- ALGS 2018
- GRF 1989
- Country
- ALGS United States
- GRF United States
- Employees
- ALGS N/A
- GRF N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- GRF Finance/Investors Services
- Sector
- ALGS Health Care
- GRF Finance
- Exchange
- ALGS Nasdaq
- GRF Nasdaq
- Market Cap
- ALGS 36.0M
- GRF 38.9M
- IPO Year
- ALGS 2020
- GRF N/A
- Fundamental
- Price
- ALGS $7.14
- GRF $9.77
- Analyst Decision
- ALGS Strong Buy
- GRF
- Analyst Count
- ALGS 1
- GRF 0
- Target Price
- ALGS $70.00
- GRF N/A
- AVG Volume (30 Days)
- ALGS 135.0K
- GRF 3.0K
- Earning Date
- ALGS 08-05-2025
- GRF 01-01-0001
- Dividend Yield
- ALGS N/A
- GRF 3.70%
- EPS Growth
- ALGS N/A
- GRF N/A
- EPS
- ALGS N/A
- GRF 1.16
- Revenue
- ALGS $3,270,000.00
- GRF N/A
- Revenue This Year
- ALGS N/A
- GRF N/A
- Revenue Next Year
- ALGS $51.55
- GRF N/A
- P/E Ratio
- ALGS N/A
- GRF $8.15
- Revenue Growth
- ALGS N/A
- GRF N/A
- 52 Week Low
- ALGS $3.76
- GRF $7.93
- 52 Week High
- ALGS $46.80
- GRF $10.19
- Technical
- Relative Strength Index (RSI)
- ALGS 50.99
- GRF 49.55
- Support Level
- ALGS $7.11
- GRF $9.76
- Resistance Level
- ALGS $8.66
- GRF $9.82
- Average True Range (ATR)
- ALGS 0.88
- GRF 0.04
- MACD
- ALGS -0.02
- GRF -0.01
- Stochastic Oscillator
- ALGS 38.79
- GRF 42.50
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About GRF Eagle Capital Growth Fund Inc.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.